Improved glucose and lipid metabolism in genetically obese mice lacking aP2

Endocrinology

Volumn 141, Issue 9, 2000, Pages 3388-3396

  Uysal, K Teoman ^a   Scheja, Ludger ^a   Wiesbrock, Sarah M ^a   Bonner Weir, Susan ^b   Hotamisligil, Gökhan S ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FATTY ACID BINDING PROTEIN; GLUCOSE; INSULIN; LIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC STIMULATION; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HOMOZYGOSITY; INSULIN RESISTANCE; INSULIN SYNTHESIS; INSULIN TOLERANCE TEST; LIPID METABOLISM; LIPOLYSIS; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

EID: 0034457430     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.9.7637     Document Type: Article

References (41)

1. The spread of the obesity epidemic in the United States 1991-1998
2. The disease burden associated with overweight and obesity
3. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models
4. Characterization of plasma lipids in genetically obese mice: The mutants obese, diabetes, fat, tubby, and lethal yellow
5. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr
6. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study
7. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
8. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity
9. Effect of fatty acids on glucose production and utilization in man
10. Mechanism of free fatty acid-induced insulin resistance in humans
11. Action of B-hydroxybutyrate, acetoacetate and palmitate on the insulin release in the perfused isolated rat pancreas
12. Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect
13. Fatty acids, lipotoxicity and insulin secretion
14. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation
15. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats
16. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications
17. Are the β-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM?
18. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes
19. Physiological properties and functions of intracellular fatty acid-binding proteins
20. Tissue specific expression of p422 protein, a putative lipid carrier, in mouse adipocytes
21. Adipocyte P2 gene: Developmental expression and homology of 5′-flanking sequences among fat cell-specific genes
22. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein
23. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice
24. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels
25. Mechanisms decreasing glucose oxidation in diabetes and starvation: Role of lipid fuels and hormones
26. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM
27. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus
28. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate
29. Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent β-adrenergic agonist virtually specific for β3 receptors. A promising antidiabetic and antiobesity agent
30. Fat cell adrenergic receptors and the control of white and brown fat cell function
31. Molecular characterization of the mouse β3-adrenergic receptor: Relationship with the atypical receptor of adipocytes
32. β3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice
33. The antidiabetic β3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin
34. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance
35. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory, defect similar to that in type 2 diabetes
36. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue
37. Deconstructing type 2 diabetes
38. Type 2 diabetes-who is conducting the orchestra?
39. Disruption of IRS-2 causes type 2 diabetes in mice
40. PPARγ activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes
41. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein